Along with COVID-19 and the flu, respiratory syncytial virus (RSV) has spread at alarming rates in recent months. Promising vaccine candidates for this common infection are now winding down their large-scale clinical trials. These vaccine candidates rely on a key advance made by Barney Graham, Jason McLellan, and colleagues in 2013. That year, Graham and McLellan, who later used similar approaches to make key contributions to the COVID-19 vaccines, provided the proof of concept for a new way of developing vaccines based on leveraging insights from structural biology. Together with colleague Man Chen, they made discoveries that paved the way for RSV vaccines that have neared the finish line, a feat Science Magazine named as a runner-up for the 2022 Breakthrough of the Year. Come join Science Magazine on 1 March at 1 p.m. ET to hear Graham, McLellan, and Chen discuss how the approach they described in 2013 is leading to what could be the first ever FDA-approved vaccines against RSV, as well as other RSV therapeutics. Gregory Zuckerman, author of multiple best-selling books, including A Shot to Save the World: The Inside Story of the Life-or-Death Race for a COVID-19 Vaccine, will share his perspective on this milestone. This event is being co-organized with the University of Texas, Austin, as part of their second Texas Science Festival.